Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?

BrilliantEye Introduction Johnson & Johnson (NYSE:JNJ) stock undoubtedly occupies a top spot in many individual stock portfolios - and portfolio managers (individual or institutional) can't be blamed - JNJ delivers like clockwork and its long-term performance (30-year return CAGR of 11.8% vs. 10.0% for the S&P 500 (SPY), coupled with its low volatility (five-year beta of just around 0.6, 30-year max. drawdown of 33% vs. 51% for the S&P 500) is truly remarkable. I am no exception to this "rule" as JNJ stock ...